Cervomed INC 8-K filings

CervoMed Inc. has filed a Form 8-K to provide updated information on its business, clinical studies, development plans, and financial position, making this information available on its website.

CervoMed announced initial Phase 2a trial data showing a reduction in a key neurodegeneration biomarker, neurofilament light (NfL), over 12 weeks of treatment with neflamapimod in patients with nonfluent variant primary progressive aphasia (nfvPPA).

CervoMed Inc. has filed a Form 8-K to disclose information regarding its business, clinical studies, development plans, and financial position, making this data available on its investor website.

CervoMed announces a new 50 mg oral tablet formulation for neflamapimod, coupled with FDA removal of a drug exposure limit, enabling a higher-dose, twice-daily regimen for future clinical trials.

CervoMed Inc. announced that initial biomarker data from its Phase 2a clinical trial of neflamapimod for nfvPPA will be presented as a late-breaking oral session at the ISFTD Annual Meeting.

CervoMed Inc. announced second quarter 2026 financial results, highlighting progress in its neflamapimod program for dementia with Lewy bodies (DLB) and providing corporate updates.

CervoMed Inc. announced its drug candidate neflamapimod has received an Innovation Passport under the UK's Innovative Licensing and Access Pathway (ILAP) for the treatment of Dementia with Lewy Bodies (DLB).

CervoMed Inc. announced new clinical, plasma biomarker, and imaging data for its drug candidate neflamapimod at the Alzheimer's Association International Conference 2026, reinforcing its potential in treating Dementia with Lewy Bodies (DLB).

CervoMed Inc. announced the completion of patient enrollment for its Phase 2a study of neflamapimod, an investigational drug for nonfluent variant primary progressive aphasia (nfvPPA), a form of frontotemporal dementia.

CervoMed Inc. announced it has received a notice of allowance from the USPTO for a new patent covering its drug candidate, neflamapimod, for treating dementia with Lewy bodies.

CervoMed Inc. has released an 8-K filing detailing business updates, clinical study information, development plans, and financial position, made available on their website.

CervoMed Inc. announced a $10.5 million private placement financing to advance its drug candidate neflamapimod and focus on strategic partnerships.

CervoMed Inc. announced the results of its 2026 Annual Meeting of Stockholders, confirming the election of eight directors, ratification of its independent auditor, and advisory approval of executive compensation and an equity incentive plan.

CervoMed announced first quarter 2026 financial results, highlighting progress in its neflamapimod program for Dementia with Lewy Bodies (DLB) and outlining anticipated milestones, subject to financing.

CervoMed announced new data from its Phase 2b RewinD-LB trial, indicating neflamapimod increased basal forebrain volume and functional connectivity in patients with dementia with Lewy bodies.

CervoMed Inc. announced updates on its neflamapimod clinical program for Lewy Body Dementia, including new MRI analyses and Phase 3 trial design.

CervoMed Inc. announced the availability of an investor presentation on its website, detailing business, clinical studies, development plans, and financial position.

CervoMed Inc. announced new analyses from its Phase 2b RewinD-LB clinical trial showing neflamapimod's greater treatment effect in dementia with Lewy bodies patients without Alzheimer's disease co-pathology.

CervoMed Inc. announced its fourth quarter and full year 2025 financial results, highlighted by positive Phase 2b DLB data and plans for a Phase 3 trial, contingent on financing.

CervoMed Inc. announced the successful completion of a Phase 1 study for a new neflamapimod formulation and selected a 50mg TID dosing regimen for its planned Phase 3 trial in dementia with Lewy bodies.

CervoMed Inc. has made an investor presentation available on its website, providing updates on its business, clinical studies, development plans, and financial position.

CervoMed Inc. announced positive Phase 2b RewinD-LB trial results for neflamapimod, demonstrating significant improvements in neuroinflammation and clinical progression in Dementia with Lewy Bodies patients.

CervoMed announced FDA alignment for its pivotal Phase 3 trial of neflamapimod in DLB, alongside reporting increased Q3 2025 net loss and a reduced cash position.

CervoMed Inc. announced it received written feedback from the FDA, aligning on key aspects of its proposed Phase 3 clinical trial for neflamapimod in dementia with Lewy bodies, paving the way for a potential New Drug Application.

CervoMed Inc. announced the appointment of David Quigley, a former Senior Partner at McKinsey & Company, to its Board of Directors, enhancing strategic and commercial expertise ahead of Phase 3 trials.

CervoMed Inc. filed an 8-K to furnish an investor presentation containing business, clinical, development, and financial information for use in various investor engagements.

CervoMed Inc. announced new Phase 2b data for neflamapimod, demonstrating significant clinical and biomarker improvements in Dementia with Lewy Bodies patients.

CervoMed Inc. announced positive 32-week data from its Phase 2b RewinD-LB trial for neflamapimod in Dementia with Lewy Bodies, showing significant reduction in clinical worsening and a key biomarker, alongside increased net loss for Q2 2025.

CervoMed Inc. announced the availability of an investor presentation on its website, detailing business, clinical, and financial information.

CervoMed Inc. announced positive 32-week data from the RewinD-LB trial extension phase, demonstrating neflamapimod's sustained effect on slowing clinical progression and reducing a key neurodegeneration biomarker in patients with Dementia with Lewy Bodies.